Is Desferrioxamine Mesilate Safe in Breastfeeding
Question
I am a breastfeeding mother and i want to know if it is safe to use Desferrioxamine Mesilate? Is Desferrioxamine Mesilate safe for nursing mother and child? Does Desferrioxamine Mesilate extracts into breast milk? Does Desferrioxamine Mesilate has any long term or short term side effects on infants? Can Desferrioxamine Mesilate influence milk supply or can Desferrioxamine Mesilate decrease milk supply in lactating mothers?
Desferrioxamine Mesilate lactation summary
- DrLact safety Score for Desferrioxamine Mesilate is 3 out of 8 which is considered Low Risk as per our analyses.
- A safety Score of 3 indicates that usage of Desferrioxamine Mesilate may cause some minor side effects in breastfed baby.
- Our study of different scientific research indicates that Desferrioxamine Mesilate may cause moderate to no side effects in lactating mother.
- Most of scientific studies and research papers declaring usage of Desferrioxamine Mesilate low risk in breastfeeding are based on normal dosage and may not hold true for higher dosage.
- While using Desferrioxamine Mesilate We suggest monitoring child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
Answer by Dr. Ru: About Desferrioxamine Mesilate usage in lactation
An iron and aluminum chelator that increases the elimination of both metals from the body.Used over short periods to treat acute poisoning from these metals and, over longer periods, to treat chronic iron overload, hemochromatosis, hemosiderosis from repeated transfusions due to thalassemia major or other chronic anemias.Administered subcutaneously, intramuscularly and intravenously. At least three cases have been reported of mothers suffering from thalassemia major who were treated with deferoxamine and breast-fed without any problems for the infant or in the iron metabolism of the milk (Pafumi 2000, Surbek 1998). Its low percentage of protein binding makes its excretion in milk possible, but its practically zero oral bioavailability prevents its transfer to the infant’s plasma via ingested breast milk, except in premature babies and the immediate neonatal period in which there may be increased intestinal permeability. According to expert authors, the possible presence of deferoxamine in breast milk is unlikely to have harmful effects in the infant (Pafumi 2000, Jensen 1995) so there is no reason to stop breastfeeding during treatment. It may be advisable to control the infant’s serum iron levels.